View Item 

Show simple item record

Getting personal: Head and neck cancer management in the era of genomic medicine
dc.contributor.authorBirkeland, Andrew C.
dc.contributor.authorUhlmann, Wendy R.
dc.contributor.authorBrenner, J. Chad
dc.contributor.authorShuman, Andrew G.
dc.date.accessioned2017-06-16T20:13:04Z
dc.date.available2017-06-16T20:13:04Z
dc.date.issued2016-04
dc.identifier.citationBirkeland, Andrew C.; Uhlmann, Wendy R.; Brenner, J. Chad; Shuman, Andrew G. (2016). "Getting personal: Head and neck cancer management in the era of genomic medicine." Head & Neck 38(S1): E2250-E2258.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/137443
dc.description.abstractBackgroundGenetic testing is rapidly becoming an important tool in the management of patients with head and neck cancer. As we enter the era of genomics and personalized medicine, providers should be aware of testing options, counseling resources, and the benefits, limitations, and future of personalized therapy.MethodsThis article offers a primer to assist clinicians treating patients in anticipating and managing the inherent practical and ethical challenges of cancer care in the genomic era.ResultsClinical applications of genomics for head and neck cancer are emerging. We discuss the indications for genetic testing, types of testing available, implications for care, privacy/disclosure concerns, and ethical considerations. Hereditary genetic syndromes associated with head and neck neoplasms are reviewed, and online genetics resources are provided.ConclusionThis article summarizes and contextualizes the evolving diagnostic and therapeutic options that impact the care of patients with head and neck cancer in the genomic era. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2250–E2258, 2016
dc.publisherWiley Periodicals, Inc.
dc.publisherOxford University Press
dc.subject.otherhead and neck
dc.subject.othercancer
dc.subject.otherpersonalized medicine
dc.subject.othergenomics
dc.subject.otherethics
dc.titleGetting personal: Head and neck cancer management in the era of genomic medicine
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137443/1/hed24132.pdf
dc.identifier.doi10.1002/hed.24132
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceAmerican Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21: 2397 – 2406.
dc.identifier.citedreference[No authors listed]. ASHG statement. Professional disclosure of familial genetic information. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. Am J Hum Genet 1998; 62: 474 – 483.
dc.identifier.citedreferenceAmerican Medical Association. Opinion 2.131 – Disclosure of familial risk in genetic testing. Code of Medical Ethics. 2007. Available at: http://www.ama‐assn.org/ama/pub/physician‐resources/medical‐ethics/code‐medical‐ethics/opinion2131.page. Accessed April 1, 2015.
dc.identifier.citedreferenceTarasoff v the Regents of the University of California, 551 P 2d 334 (California 1976).
dc.identifier.citedreferencePate v Thelkel, 661 So 2d 278 (Florida 1995).
dc.identifier.citedreferenceSafer v Estate of Pack, 677 A2d 1188 (NJ Super Ct App Div 1996).
dc.identifier.citedreferenceChapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507 – 2516.
dc.identifier.citedreferenceKeedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non‐small‐cell lung cancer considering first‐line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121 – 2127.
dc.identifier.citedreferenceSlamon DJ, Leyland–Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783 – 792.
dc.identifier.citedreferenceRubin EH, Allen JD, Nowak JA, Bates SE. Developing precision medicine in a global world. Clin Cancer Res 2014; 20: 1419 – 1427.
dc.identifier.citedreferenceBonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567 – 578.
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F, et al. Platinum‐based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116 – 1127.
dc.identifier.citedreferenceBrose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine‐refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‐blind, phase 3 trial. Lancet 2014; 384: 319 – 328.
dc.identifier.citedreferenceSchlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine‐refractory thyroid cancer. N Engl J Med 2015; 372: 621 – 630.
dc.identifier.citedreferenceWells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double‐blind phase III trial. J Clin Oncol 2012; 30: 134 – 141.
dc.identifier.citedreferenceElisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639 – 3646.
dc.identifier.citedreferenceAng KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24 – 35.
dc.identifier.citedreferenceNichols AC, Chan‐Seng‐Yue M, Yoo J, et al. A pilot study comparing HPV‐positive and HPV‐negative head and neck squamous cell carcinomas by whole exome sequencing. ISRN Oncol 2012; 2012: 809370.
dc.identifier.citedreferenceEverett JN, Gustafson SL, Raymond VM. Traditional roles in a non‐traditional setting: genetic counseling in precision oncology. J Genet Couns 2014; 23: 655 – 660.
dc.identifier.citedreferenceConley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014; 41: 297 – 299.
dc.identifier.citedreferenceAppelbaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982; 5: 319 – 329.
dc.identifier.citedreferencePentz RD, White M, Harvey RD, et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 2012; 118: 4571 – 4578.
dc.identifier.citedreferenceCrites J, Kodish E. Unrealistic optimism and the ethics of phase I cancer research. J Med Ethics 2013; 39: 403 – 406.
dc.identifier.citedreferenceWeeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367: 1616 – 1625.
dc.identifier.citedreferenceJemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69 – 90.
dc.identifier.citedreferenceLacko M, Braakhuis BJ, Sturgis EM, et al. Genetic susceptibility to head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2014; 89: 38 – 48.
dc.identifier.citedreferenceStransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157 – 1160.
dc.identifier.citedreferenceAgrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154 – 1157.
dc.identifier.citedreferenceCancer Genome Atlas Research Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576 – 582.
dc.identifier.citedreferenceSchmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 2014; 40: 390 – 404.
dc.identifier.citedreferenceCulos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first‐line treatment options. Ann Pharmacother 2013; 47: 519 – 526.
dc.identifier.citedreferenceBombard Y, Offit K, Robson ME. Risks to relatives in genomic research: a duty to warn? Am J Bioeth 2012; 12: 12 – 14.
dc.identifier.citedreferenceBrierley KL, Blouch E, Cogswell W, et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J 2012; 18: 303 – 309.
dc.identifier.citedreferenceBeauchamp TL, Childress JF. Principles of biomedical ethics. 7th ed. New York, NY: Oxford University Press; 2012. p 480.
dc.identifier.citedreferencede Castro G Jr, Negrão MV. The Cancer Genome Atlas findings in head and neck cancer: a renewed hope. Curr Opin Oncol 2014; 26: 245 – 246.
dc.identifier.citedreferenceLindor NM, McMaster ML, Lindor CJ, Greene MH, et al. Concise handbook of familial cancer susceptibility syndromes – second edition. J Natl Cancer Inst Monogr 2008; 38: 1 – 93.
dc.identifier.citedreferenceTan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400 – 407.
dc.identifier.citedreferenceAmerican Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565 – 612.
dc.identifier.citedreferenceEiler ME, Frohnmayer D, Frohnmayer L, Larsen K, Owen J. Fanconi anemia: guidelines for diagnosis and management. Eugene, OR: Fanconi Anemia Research Fund, Inc; 2008. p 391.
dc.identifier.citedreferenceLenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915 – 1942.
dc.identifier.citedreferenceThakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type I (MEN1). J Clin Endocrinol Metab 2012; 97: 2990 – 3011.
dc.identifier.citedreferenceFerner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44: 81 – 88.
dc.identifier.citedreferenceEvans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4: 16.
dc.identifier.citedreferenceMaher ER, Neumann HP, Richard S. von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19: 617 – 623.
dc.identifier.citedreferenceACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med 2012; 14: 759 – 761.
dc.identifier.citedreferenceQuillin JM, Bodurtha JN, Siminoff LA, Smith TJ. Physicians’ current practices and opportunities for DNA banking of dying patients with cancer. J Oncol Pract 2011; 7: 183 – 187.
dc.identifier.citedreferenceBombard Y, Robson M, Offit K. Revealing the incidentalome when targeting the tumor genome. JAMA 2013; 310: 795 – 796.
dc.identifier.citedreference1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population‐scale sequencing. Nature 2010; 467: 1061 – 1073.
dc.identifier.citedreferenceForbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 ( Database issue ): D805 – D811.
dc.identifier.citedreferenceStadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol 2014; 32: 687 – 698.
dc.identifier.citedreferenceZettler PJ, Sherkow JS, Greely HT. 23andME, the Food and Drug Administration, and the future of genetic testing. JAMA Intern Med 2014; 174: 493 – 494.
dc.identifier.citedreferenceAmerican College of Medical Genetics Board of Directors. ACMG statement on direct‐to‐consumer genetic testing. Genet Med 2004; 6: 60.
dc.identifier.citedreference.National Society of Genetic Counselors. Direct to consumer testing. Available at: http://nsgc.org/p/cm/ld/fid=14#directconsumer. Accessed April 1, 2015.
dc.identifier.citedreferenceHudson K, Javitt G, Burke W, Byers P; American Society of Human Genetics Social Issues Committee. ASHG statement on direct‐to‐consumer genetic testing in the United States. Obstet Gynecol 2007; 110: 1392 – 1395.
dc.identifier.citedreferenceReilly PR, Boshar MF, Holtzman SH. Ethical issues in genetic research: disclosure and informed consent. Nat Genet 1997; 15: 16 – 20.
dc.identifier.citedreferenceRobson ME, Storm CD, Weitzel J, Wollins DS, Offit K; American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28: 893 – 901.
dc.identifier.citedreferenceHampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 2015; 17: 70 – 87.
dc.identifier.citedreferenceUhlmann WR, Guttmacher AE. Key internet genetics resources for the clinician. JAMA 2008; 299: 1356 – 1358.
dc.identifier.citedreferenceHealth Insurance Portability and Accountability Act of 1996. Pub. L. No: 104–191.
dc.identifier.citedreference[No authors listed]. Modifications to HIPAA Privacy, Security, Enforcement, and Breach Notification rules under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; other modifications to the HIPAA rules. Fed Regist 2013; 78: 5565 – 5702.
dc.identifier.citedreferenceGenetic Information Non‐Discrimination Act of 2008. Pub. L. No: 110–233.
dc.identifier.citedreferenceSarata AK, DeBergh JV, Staman J. The Genetic Information Nondiscrimination Act of 2008 and the Patient Protection and Affordable Care Act of 2010: overview and legal analysis of potential interactions. Congressional Research Service; 2011. pp 1–17.
dc.identifier.citedreferenceEEOC v Fabricut, Inc., 13‐CV‐248‐CVE‐PJC (Oklahoma 2013).
dc.identifier.citedreferenceEEOC v. Founders Pavilion, 6:13‐CV‐06250 (New York 2013).
dc.identifier.citedreferenceRoss LF, Saal HM, David KL, Anderson RR; American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med 2013; 15: 234 – 245.
dc.identifier.citedreferenceRichards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Available at: https://www.acmg.net/docs/Standards Guidelines for the Interpretation of Sequence Variants.pdf. Accessed April 1, 2015.
dc.identifier.citedreferenceCassa CA, Savage SK, Taylor PL, Green RC, McGuire AL, Mandl KD. Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res 2012; 22: 421 – 428.
dc.identifier.citedreferenceGreen RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15: 565 – 574.
dc.identifier.citedreferenceKlitzman R, Appelbaum PS, Chung W. Return of secondary genomic findings vs patient autonomy: implications for medical care. JAMA 2013; 310: 369 – 370.
dc.identifier.citedreferenceWolf SM, Annas GJ, Elias S. Point‐counterpoint. Patient autonomy and incidental findings in clinical genomics. Science 2013; 340: 1049 – 1050.
dc.identifier.citedreferenceBurke W, Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings? We need to talk! Genet Med 2013; 15: 854 – 859.
dc.identifier.citedreferenceU.S. Government, Presidential Commission for the Study of Bioethical Issues. Anticipate and communicate. Ethical management of incidental and secondary findings in the clinical, research, and direct‐to‐consumer contexts. Washington, DC: Progressive Management; 2013.
dc.identifier.citedreferenceDickert N, Wendler D. Ancillary care obligations of medical researchers. JAMA 2009; 302: 424 – 428.
dc.identifier.citedreferenceRangel EK. The management of incidental findings in neuro‐imaging research: framework and recommendations. J Law Med Ethics 2010; 38: 117 – 126.
dc.identifier.citedreferenceACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome‐scale sequencing. Genet Med 2015; 17: 68 – 69.
dc.identifier.citedreferenceDomchek S, Weber BL. Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 2008; 26: 16 – 17.
dc.identifier.citedreferenceSyvänen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2: 930 – 942.
dc.identifier.citedreferenceHindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome‐wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009; 106: 9362 – 9367.
dc.identifier.citedreferenceOffit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The “duty to warn” a patient’s family members about hereditary disease risks. JAMA 2004; 292: 1469 – 1473.
dc.identifier.citedreferenceMacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet 2013; 83: 221 – 231.
dc.identifier.citedreferenceShuman AG, Shaha AR, Tuttle RM, Fins JJ, Morris LG. Medullary thyroid carcinoma: ethical issues for the surgeon. Ann Surg Oncol 2012; 19: 2102 – 2107.
dc.identifier.citedreferenceSulmasy DP. On warning families about genetic risk: the ghost of Tarasoff. Am J Med 2000; 109: 738 – 739.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed24132.pdf
Size:
106.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.